Mr. Marcelo C. Mansur
CEO and President
Nortec Quimica SA
Rua Dezessete, 200, Distrito Industrial
Xerem
Duque de Caxias - RJ
25250-612
BrazilFEI 3007616930Issued Dec 8, 2022Center for Drug Evaluation and Research | CDER
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3007616930.
Violations1
Issue DateDec 8, 2022
Product TypeDrugs
StatusClosed
Closeout LetterOct 30, 2023
Letter Details
Firm
Nortec Quimica SA
Location
Mr. Marcelo C. Mansur
CEO and President
Nortec Quimica SA
Rua Dezessete, 200, Distrito Industrial
Xerem
Duque de Caxias - RJ
25250-612
Brazil
FEI Number
3007616930
Country
Brazil
Issue Date
December 08, 2022
Issuing Office
Center for Drug Evaluation and Research | CDER
Product Type
Drugs
Status
Closed
Closeout Letter
October 30, 2023
Summary
Nortec Quimica SA, a Brazilian active pharmaceutical ingredient (API) manufacturer, failed to maintain adequate controls over computerized systems used in drug manufacturing, resulting in adulterated APIs exported to the United States. FDA inspectors found over 100 deleted analytical files in spectrophotometer computers, including batch records for APIs shipped to the U.S., with no system security, individual user attribution, password protection, or data backup procedures in place. The facility's stand-alone analytical systems used common usernames without login requirements, allowing analysts unrestricted access to delete and overwrite critical manufacturing and testing data.
Nortec Quimica SA FDA Warning Letter, December 8, 2022